Kolaja KL - Search Results

1

Developing in vitro assays to transform gastrointestinal safety assessment: potential for microphysiological systems.

Peters MF, Choy AL, Pin C, Leishman DJ, Moisan A, Ewart L, Guzzie-Peck PJ, Sura R, Keller DA, Scott CW, Kolaja KL. Peters MF, et al. Among authors: kolaja kl. Lab Chip. 2020 Apr 7;20(7):1177-1190. doi: 10.1039/c9lc01107b. Epub 2020 Mar 4. Lab Chip. 2020. PMID: 32129356 Review.

2

Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.

Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL. Peters MF, et al. Among authors: kolaja kl. Cardiovasc Toxicol. 2015 Apr;15(2):127-39. doi: 10.1007/s12012-014-9268-9. Cardiovasc Toxicol. 2015. PMID: 25134468 Review.

3

Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs.

Belair DG, Visconti RJ, Hong M, Marella M, Peters MF, Scott CW, Kolaja KL. Belair DG, et al. Among authors: kolaja kl. Toxicol In Vitro. 2020 Oct;68:104928. doi: 10.1016/j.tiv.2020.104928. Epub 2020 Jul 3. Toxicol In Vitro. 2020. PMID: 32622998 Free article.

4

Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspective.

Pointon A, Maher J, Davis M, Baker T, Cichocki J, Ramsden D, Hale C, Kolaja KL, Levesque P, Sura R, Stresser DM, Gintant G. Pointon A, et al. Among authors: kolaja kl. Lab Chip. 2021 Feb 9;21(3):458-472. doi: 10.1039/d0lc01040e. Lab Chip. 2021. PMID: 33471007

5

Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches.

Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Lamore SD, et al. Among authors: kolaja kl. Chem Res Toxicol. 2020 Jan 21;33(1):125-136. doi: 10.1021/acs.chemrestox.9b00387. Epub 2020 Jan 10. Chem Res Toxicol. 2020. PMID: 31840498 Review.

6

Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations.

Cohen JD, Babiarz JE, Abrams RM, Guo L, Kameoka S, Chiao E, Taunton J, Kolaja KL. Cohen JD, et al. Among authors: kolaja kl. Toxicol Appl Pharmacol. 2011 Nov 15;257(1):74-83. doi: 10.1016/j.taap.2011.08.020. Epub 2011 Aug 27. Toxicol Appl Pharmacol. 2011. PMID: 21906609 Free PMC article.

7

Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.

Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL. Guo L, et al. Among authors: kolaja kl. Toxicol Sci. 2011 Sep;123(1):281-9. doi: 10.1093/toxsci/kfr158. Epub 2011 Jun 20. Toxicol Sci. 2011. PMID: 21693436

8

Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.

Guo L, Coyle L, Abrams RM, Kemper R, Chiao ET, Kolaja KL. Guo L, et al. Among authors: kolaja kl. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19. Toxicol Sci. 2013. PMID: 24052561

9

The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts.

Guo L, Qian JY, Abrams R, Tang HM, Weiser T, Sanders MJ, Kolaja KL. Guo L, et al. Among authors: kolaja kl. Cell Physiol Biochem. 2011;27(5):453-62. doi: 10.1159/000329966. Epub 2011 Jun 15. Cell Physiol Biochem. 2011. PMID: 21691062 Free article.

10

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.

Belair DG, Lu G, Waller LE, Gustin JA, Collins ND, Kolaja KL. Belair DG, et al. Among authors: kolaja kl. Sci Rep. 2020 Feb 18;10(1):2864. doi: 10.1038/s41598-020-59542-x. Sci Rep. 2020. PMID: 32071327 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters